1. Mason R. P. Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil. Vasc Health Risk Manag, 2011; 7:405–16.
2. Motoshima H., Araki E. RAAS and insulin resistance. Nihon Rinsho, 2012;70 (9): 1542–9.
3. Kasal D. A., Schiffrin E. L. Angiotensin II, aldosterone, and anti-inflammatory lymphocytes: interplay and therapeutic opportunities. Int J Hypertens, 2012; 2012:829786.
4. Morris Matthew E., Fletcher J. A., Thyfault J. P. The role of angiotensin II in nonalcoholic steatohepatitis. Mol Cell Endocrinol, 2012 May 11.
5. Jing F., Mogi M., Horiuchi M. Role of renin-angiotensin-aldocterone system in adipose tissue dysfunction. Mol Cell Endocrinol, 2012 Mar 23.
6. Fliser D., Buchholz K., Haller H. et al. Anti-inflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Cardiovasc Ther and Prophylaxis, 2010; 9 (7):14–22.
7. Lorenzen J. M., Neuhoeffer H., David S. Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension – results from the EUTOPIA trial. Atherosclerosis, 2010; 209 (1):184–8.
8. Takiguchi S., Ayaori M., Uto-Kondo H. et al. Olmesartan improves endothelial function in hypertensive patients: link with extracellular superoxide dismutase. Hypertens Res, 2011; 34 (6):686–92.
9. Pimenta E., Oparil S. Impact of olmesartan on blood pressure, endothelial function and cardiovascular outcomes. Integr Blood Press Control, 2010; 3:113–23.
10. Ishizawa K., Izawa-Ishizawa Y., Dorjsuren N. et al. Angiotensin II receptor blocker attenuates PDGF-induced mesangial cell migration in a receptor-independent manner. Nephrol Dial Transplant, 2010; 25 (2):364–72.
11. Minatoguchi S., Aoyama T., Kawai N. et al. Comparative effect of candesartan and amlodipine and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan on early morning hypertension and heart rate. Blood Press, 2013 Jan 18.
12. Arao T., Okada Y., Mori H. et al. Antihypertensive and methabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension. Endocr J, 2013 Jan 10.
13. Nakayama S., Watada H., Mita T. et al. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res, 2008; 31 (1):7–13.
14. Punzi H. A., Lewin A., Li W. et al. Efficacy/safety of olmesartan medoxomil vs. losartan potassium in naive versus previously treated subjects with hypertension. Adv Ther, 2012; 29 (6):524–37.
15. Hirohata A., Yamamoto K., Miyoshi T. et al. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol, 2010; 55 (10):976–82.
16. Hirohata A., Yamamoto K., Miyoshi T. et al. Four-year clinical outcomes of the OLIVUSEx (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial. Atherosclerosis, 2012; 220 (1):134–8.
17. Manotham K., Ongvilawan B., Uruspone P. et al. Angiotensin II receptor blocker partially ameliorated intrarenal hypoxia in chronic kidney disease patients: a pre-/post-study. Intern Med J, 2012; 42 (4): e33–7.
18. Toyama T., Sato C., Koyama K. et al. Olmesartan improves coronary flow reserve of hypertensive patients using coronary magnetic resonance imaging compared with amlodipine. Cardiology, 2012; 122 (4):230–6.
